Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe

about

Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe

Item

http://www.wikidata.org/entity/Q57482841

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Bioavailability of dexlansopra ...... ric tube or orally via syringe

@en

Bioavailability of dexlansopra ...... ric tube or orally via syringe

@nl

type

Item

label

Bioavailability of dexlansopra ...... ric tube or orally via syringe

@en

Bioavailability of dexlansopra ...... ric tube or orally via syringe

@nl

prefLabel

Bioavailability of dexlansopra ...... ric tube or orally via syringe

@en

Bioavailability of dexlansopra ...... ric tube or orally via syringe

@nl

P1476

Bioavailability of dexlansopra ...... ric tube or orally via syringe

@en

P2093

Maria Claudia Perez

http://www.w3.org/2001/XMLSchema#string

Michael Kukulka

http://www.w3.org/2001/XMLSchema#string

Sai Nudurupati

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacology of proton pump inhibitors

Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis

Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.

Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.

Eosinophilic esophagitis: a newly established cause of dysphagia

Guidelines for the diagnosis and management of gastroesophageal reflux disease.

Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations.

Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease.

Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.

Prevalence and risk factors for dysphagia: a USA community study

P304

381-389

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CEG.S138580

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30323643

http://www.w3.org/2001/XMLSchema#string

P921

gastroenterology

P932

6177519

http://www.w3.org/2001/XMLSchema#string